Eisai drops sepsis blockbuster, but files first-in-class epilepsy drug
This article was originally published in Scrip
Executive Summary
Eisai will not be making US/EU/Japanese regulatory filings for its sepsis drug eritoran (E5564) – which was expected to be a blockbuster to counter generic competition to the firm's Alzheimer's drug Aricept – as had been planned as a key study, ACCESS, did not meet its primary endpoint. On a positive note, however, the firm says it will be filing in the US and EU its first-in-class partial epilepsy therapy perampanel (E2007).